Perifollicular Pink Halo: A Potential Dermoscopic Marker of Inflammation in Central Centrifugal Cicatricial Alopecia

The document summarizes findings from two studies on cancer treatments. The first study with 54 patients (40 untreated and 14 pretreated) focused on immune cell diversity in mesothelioma, revealing that CD8+ TILs were predominant in the tumor stroma and that certain immune markers could predict chemotherapy response and prognosis, suggesting TIM-3 as a potential new treatment target. The second study involved 52 patients with advanced non-small cell lung cancer treated with nivolumab monotherapy, showing a 23% ORR, a median OS of 19.4 months, and a 41% 24-week PFS rate, confirming nivolumab's tolerability and durable efficacy. The document also references the BIRCH study on atezolizumab in advanced NSCLC but does not detail its results.